Close Menu

This article has been updated with a statement from Guardant Health.

NEW YORK (GenomeWeb) – Foundation Medicine has filed a lawsuit against Guardant Health, alleging that the company willfully infringes one of its recently awarded patents.

In the complaint, filed yesterday with the US District Court for the Eastern District of Texas, Marshall Division, Foundation Medicine claims that the Guardant360 cell-free tumor DNA liquid biopsy test infringes its US Patent No. 9,340,830.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nov
18
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Nov
19
Sponsored by
Stilla

Fluorescent proteins or self-labeling tags are invaluable tools for studying protein dynamics in living cells using fluorescence microscopy. However, quantitative imaging requires physiological levels of expression of the target protein of interest (POI), especially when stoichiometric interactions of the POI need to be investigated.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).